Latest Plans:
RSS
Nov 19
C.51. Bangkok: XVI International Conference on AIDS PDF print email
Written by Administrator   
Monday, 08 February 2010 05:23
There are no translations available.


WePeA5599 Poster

Atherosclerosis and AIDS : Homology between atherogenic Marek's herpes virus and LDL receptor, between cytomegalovirus (CMV) and LDL-related receptor, and between HIV-1 VIF and phospholipase A2.


TRAN Guy Mong Ky ([1], [5]), CAPRANI Adrien ([3], [5]), KIRKIACHARIAN Serge ([2]), MAURISSON Gilbert ([4], [5]).

1 University Paris-Sud XI ; correspondence: 31 Av du Bois, Châtenay-Malabry, France. E-mail : This e-mail address is being protected from spambots. You need JavaScript enabled to view it
2 Therapeutic Chemistry, Faculty Pharmacy, University Paris-Sud XI, Châtenay-Malabry. E-mail : This e-mail address is being protected from spambots. You need JavaScript enabled to view it .
3 University 7-Denis Diderot, CNRS Tour 33/34 ESA7057, 2 Place Jussieu, Paris Cedex 05. E-mail : This e-mail address is being protected from spambots. You need JavaScript enabled to view it .
4 Centre Médical Europe, 44 rue d'Amsterdam, Paris. E-mail : This e-mail address is being protected from spambots. You need JavaScript enabled to view it .
5 Association Positifs, BP 230 75865 Paris Cedex 18. E-mail : This e-mail address is being protected from spambots. You need JavaScript enabled to view it

Aids is characterized by the occurrence of severe atherosclerosis in very young patients. This prompted us to look for the physiopathology of atherosclerosis in this especially susceptible but unusual population. Our objective is to screen for viruses inducing atherosclerosis.

We looked on Marek's herpes virus (Fabricant C.G., 1978), which can induce in chicken coronary disease even with a diet without cholesterol. CMV is also a good candidate, as it enhances the recurrences of coronary stenosis after stent. Lastly, in transgenic mouse, phospholipase A2 is responsible of atherosclerosis (Ivandic B., 1999). By comparison of amino acid sequences, we found 3 significant homologies :

  1. Marek's herpes virus 132bp repeat (sequence LHTS... TICRNK FLCLLP) ...is a rabbit LDL cholesterol receptor ( repeat V)-like (CIHSSÉSLC-ss-CKNK... RQFVC-ss-CPVL) in tridimensional cysteine bridged [-ss-] structure.
  2. CMV TRL6 (sequence WKTV...DQWLCNVTGIGNAT) is a LDL related receptor-like. (WHSV...QWLCD).
  3. HIV-1 VIF protein has the tridimensionnal structure and active site residues (His, Ser) of a phospholipase A.

Conclusion:

These striking homologies between virus and cholesterol receptors, and between HIV-1 VIF and phospholipase A may explain the abnormal occurrence of severe atherosclerosis in such a young population as AIDS. Treatment must focus on anti-herpes virus drugs (and bee propolis, an antiviral natural product) as well as on VIF for a component of AIDS vaccine and anti-phospholipase drug.


Last Updated on Sunday, 14 March 2010 04:16
 
C.50a. Toulon 2004 PDF print email
Written by Administrator   
Monday, 08 February 2010 04:28
There are no translations available.


13th International Symposium on HIV & Emerging Infectious Diseases


For all abstracts: http://www.isheid.com/



MOLECULAR HOMOLOGY BETWEEN ALPHA-DEFENSIN AND SCRUB TYPHUS RICKETTSIA ORIENTIA TSUTSUGAMUSHI 56K TYPE SPECIFIC ANTIGEN

Authors : TRAN M.K.G.[1], [5], KIRKIACHARIAN S.[2], MAURISSON G.[3], [5], CAPRANI A.[4], [5]

1 University Paris-Sud XI ; correspondence: 31 Av du Bois, Châtenay-Malabry, France.
2 Therapeutic Chemistry, Faculty Pharmacy, University Paris-Sud XI, Châtenay-Malabry.
3 Centre Médical Europe, 44 rue d'Amsterdam, Paris
4 CNRS UMR, University 7-Denis Diderot, CNRS UMR 7057, 2 Place Jussieu, Paris Cedex 05.
5 Association Positifs, BP 230 75865 Paris Cedex 18.


INTRODUCTION

The challenge of an HIV vaccine is not yet solved, but new areas were appearing with advances coming from unexpected directions, such as amelioration of HIV infection in some (about 40%) but not all patients infected by scrub typhus in Thailand (Watt G., 2001, 2000). In the same time, elucidation of the mysterious protective factor in long-term nonprogressors conducted to the discovery of a-defensin (Zhang L., 2002). The crucial Nef protein was in fact an a-defensin-like homolog (Tran M.K.G., 2003). What became evident then is the strength of molecular mimicry as an unique method for unifying these 3 discoveries, at the level of amino acid sequences (as we shall see further), at the cross road of these 3 apparently independent data.

Last Updated on Sunday, 14 March 2010 04:16
 
C.50. Toulon 2004 PDF print email
Written by Administrator   
Sunday, 07 February 2010 21:26
There are no translations available.

13th International Symposium on HIV & Emerging Infectious Diseases

(for all abstracts: goto http://www.isheid.com).
Abstracts of Tran MKG & POSITIFS association.

AGREE ABSTRACTS

  • MOLECULAR HOMOLOGY BETWEEN ALPHA-DEFENSIN AND SCRUB TYPHUS RICKETTSIA ORIENTIA TSUTSUGAMUSHI 56KD TYPE SPECIFIC ANTIGEN
  • HIV-1 Protease Is A Metalloproteinase Containing A Copper-Binding Motif Gly His Lys (GHK) At Residues 68-70

NON AGREE ABSTRACTS

  • The Scorpion Venom Model Of Aids: Scrub Typhus Rickettsia Orientia Tsutsugamushi 56kd Type Specific Antigen Has A Common Motif With HIV-1 Nef In The Alpha-defensin-like Region.
  • Aids and Atherosclerosis: Homology Between Atherogenic Chicken Marek's Disease Herpes Virus and LDL Receptor
  • The Scorpion Venom Model Of Aids: Feline Leukemia Virus (FeLV 61C Inducing Aids) Envelope Is Homologous To A Scorpion Venom
  • Molecular Homology Between RANTES, MIP 1alpha, MIP 1beta Chemokines, HIV-1,-2 SIV Envelope GP120 V2 Loop And Scorpion Venom Tityus TS-VI

Toulon 2004 : Abstracts

13th International Symposium on HIV & Emerging Infectious Diseases


6 abstracts for Toulon :

Authors : TRAN M.K.G.[1], [5], KIRKIACHARIAN S.[2], MAURISSON G.[3], [5], CAPRANI A.[4], [5]

  • 1 University Paris-Sud XI ; correspondence: 31 Av du Bois, Châtenay-Malabry, France.
  • 2 Therapeutic Chemistry, Faculty Pharmacy, University Paris-Sud XI, Châtenay-Malabry.
  • 3 Centre Médical Europe, 44 rue d'Amsterdam, Paris
  • 4 CNRS UMR, University 7-Denis Diderot, CNRS UMR 7057, 2 Place Jussieu, Paris Cedex 05.
  • 5 Positifs Association, BP 230 75865 Paris Cedex 18.


2 AGREE ABSTRACTS


Poster's form MOLECULAR HOMOLOGY BETWEEN ALPHA-DEFENSIN

AND SCRUB TYPHUS RICKETTSIA ORIENTIA TSUTSUGAMUSHI 56KD

TYPE SPECIFIC ANTIGEN

TRAN M.K.G.[1], [3], KIRKIACHARIAN S.[2], MAURISSON G.[3], CAPRANI A.[3]

1 Univ Paris-Sud, 2 Therap Chem, Fac Pharm, 92290 Chatenay-Mb, 3 Positifs Association

1) Zhang L.(2002) discovered an a-defensin isotype [differing by isoleucine 28 (Ileu 28 or I 28), instead of phenylalanine (Phe or F) in classical commercial a-defensin] as the natural protective factor against HIV-1 in long-term nonprogressors remaining a life without treatment.
2) Watt G (2000, 2001) remarked a beneficial effect of sera from scrub typhus Rickettsia (Orientia Tsutsugamushi) [Rick.Or.Tsu.]-infected HIV-1+ patients on HIV-1 replication, suggesting a protective cross-reactive antibody.
3) Tran M.K.G. described a molecular homology between Nef and a -defensin (Warsaw Conf., Poland, 2003), then between Nef and Rick.Or.Tsu. 56 Kd type specific antigen (tsa 56) (this Toulon Conf., 2004) centered on the common tetrapeptide GIRY. It is noteworthy that Zhang's a-defensin variant (I 28) is 20 times more protective against HIV-1 than commercial a-defensin (F 28), pointing to an important role for this isoleucine 28 residue.

Last Updated on Friday, 19 March 2010 18:02
 
C.48. XIVème Conférence Internationale sur le Sida et 12ème Symposium International sur le VIH PDF print email
Written by Administrator   
Friday, 05 February 2010 22:48
There are no translations available.

XIVème Conférence Internationale sur le Sida (Barcelone, juillet 2002) &
12ème Symposium International sur le VIH et les maladies infectieuses émergentes (Toulon, juin 2002).


Présentation

À l'occasion de la XIVème Conférence Internationale sur le Sida de Barcelone et du 12ème Symposium International sur le Sida de Toulon, l'association POSITIFS a soumis plusieurs publications (abstracts) concernant l'infection à VIH et d'autres sujets (hépatites chroniques, Alzeihmer, maladies à prion, ostéoporose, etc.).

La plupart de ces publications ont été réalisées en collaboration avec le Dr MKG Tran qui, depuis plusieurs années, poursuit ses travaux de recherches sur les homologies moléculaires, aussi bien dans le cadre de l'infection à VIH que dans d'autres domaines médicaux.

En raison de la participation au congrès Barcelone de plusieurs milliers de personnes, la sélection des publications soumises par les congressistes a été particulièrement draconienne.
L'ensemble des publications soumises par l'association POSITIFS au congrès de Barcelone, et qui n'avaient pas été acceptées, ont été toutes retenues par le congrès de Toulon.

Last Updated on Sunday, 14 March 2010 04:17
 
C.29. Pao pereira PDF print email
Written by Administrator   
Tuesday, 02 February 2010 05:26
There are no translations available.

Enfin des publications!


Des résultats concernant des patients au stade ARC traités avec Pao pereira entre 1990 et 1991 viennent en effet d'être soumis, en janvier 1994, au comité de lecture d'un journal médical international, afin d'obtenir leur publication officielle (D. Donadio et coll., "Tolerance and Feasability of a 12 months Therapy Using the Antiretroviral Agent PB100 in Aids-related-complex Patients").

Cette étude a été réalisée au CHU de Montpellier sur dix patients au stade ARC, durant une période d'un an. Dix autres patients n'ont pu être retenus pour cette publication dans la mesure où, bien qu'ils aient été traités sur plus d'un an, leurs bilans biologiques n'avaient pas été faits assez régulièrement pour être exploités statistiquement. Il s'agissait d'une étude pilote de phase II réalisée, rappelons-le, afin d'évaluer avant tout la tolérance de Pao pereira (1g/jour) chez des personnes séropositives au stade ARC.

Les résultats sur un an ne montrent aucune intolérance ni effet secondaire. On note une amélioration des lymphocytes T4 de plus de 100/mm3 (les T4 étaient au départ entre 200 et 400/mm3), une amélioration du rapport T4/T8 et une bêta-2-microglobuline qui est restée en dessous de 5 mg/l (le taux initial était de 3 à 4 mg/l). Enfin, sur les neuf patients suivis régulièrement, aucune infection opportuniste, ni tumeur, ne sont survenues.

Last Updated on Sunday, 14 March 2010 04:18
 


Page 10 of 15